Search

Anatomy of two biotech deals worth $20B

ANATOMY OF TWO BIOTECH DEALS WORTH $20B

Analysts had forecast a blockbuster year for life science M&As, with the tax reforms taking effect and Big Pharma scrambling for late-stage...

WALL STREET PAYDAY: 4 banks made a killing from Monday's $20 billion in biotech deals

WALL STREET PAYDAY: 4 BANKS MADE A KILLING FROM MONDAY'S $20 BILLION IN BIOTECH DEALS

Biotech mergers and acquisitions are off to a hot start in 2018. On Monday, French drugmaker Sanofi spent $11.6 billion to buy US hemophilia...

 
 
 
Two drug companies are exploding after a pair of biotech mega-deals

TWO DRUG COMPANIES ARE EXPLODING AFTER A PAIR OF BIOTECH MEGA-DEALS

Markets Insider French drugmaker Sanofi is acquiring biotech company Bioverativ in a $11.6 billion deal. Celgene is acquiring Juno...

Sanofi is buying Bioverativ for $11.6 billion

SANOFI IS BUYING BIOVERATIV FOR $11.6 BILLION

Benoit Tessier/Reuters French drugmaker Sanofi is acquiring biotech company Bioverativ in a $11.6 billion deal. It's the biggest deal...

 
 
 

DEVELOPING A SANOFI CAST-OFF, IMPACT BIOMEDICINES NOW SUBJECT OF RUMORED $7B CELGENE ACQUISITION DEAL

A startup developing the once-discarded fedratinib, a drug cast off from Sanofi due to safety concerns back in 2013, is now the subject...

2 UNDERAPPRECIATED BIOTECH STOCKS TO BUY IN 2018

Why Horizon Pharma and Sanofi are three cheap stocks worth considering in 2018.

 
 
 

PLANT-EXPRESSED FC-FUSION PROTEIN TETRAVALENT DENGUE VACCINE WITH INHERENT ADJUVANT PROPERTIES

Abstract Dengue is a major global disease requiring improved treatment and prevention strategies. The recently licensed Sanofi-Pasteur...

 
 
 
Philippines wants money back from Sanofi for dengue vaccine

PHILIPPINES WANTS MONEY BACK FROM SANOFI FOR DENGUE VACCINE

MANILA, Philippines - The Philippine government will demand a refund of 3.5 billion pesos from vaccine maker Sanofi Pasteur and look...

THE PHILIPPINES SUSPENDS SANOFI'S DENGUE VACCINE AFTER 730,000+ CHILDREN ARE IMMUNIZED

Amid mounting public concern, Sanofi explained its “new findings” at a news conference in Manila.

 
 
 
 
 
 
Biotech Roundup: Opioid News, ASH Preview, Boston Bio IPOS & More

BIOTECH ROUNDUP: OPIOID NEWS, ASH PREVIEW, BOSTON BIO IPOS & MORE

The rising death toll from opioids has prompted policymakers to try various ways to take on the problem. President Trump's opioid commission...

States investigate pharma companies, CVS Health as diabetes drug prices reach record highs

STATES INVESTIGATE PHARMA COMPANIES, CVS HEALTH AS DIABETES DRUG PRICES REACH RECORD HIGHS

The United States is one of the few developed countries without regulations on prescription drug pricing.

 
 
 
Terminated Blood Cancer Drug Springs Back to Life at SD Biotech

TERMINATED BLOOD CANCER DRUG SPRINGS BACK TO LIFE AT SD BIOTECH

A blood cancer drug resurrected by the scientist who helped discover the compound, and who shepherded it through years of R&D, got...

Eli Lilly to Pursue mRNA Cancer Vaccines with CureVac Pact

ELI LILLY TO PURSUE MRNA CANCER VACCINES WITH CUREVAC PACT

Eli Lilly is getting a foothold in messenger RNA cancer vaccines through a deal with CureVac that could develop up to five new therapies....

 
 
 
Bio Roundup: Graham-Cassidy, Axovant Fail, SpringWorks Launches & More

BIO ROUNDUP: GRAHAM-CASSIDY, AXOVANT FAIL, SPRINGWORKS LAUNCHES & MORE

After drug pricing, count drug shortages among the hot button issues sparking patient ire. Last year, the FDA says, 23 drug shortages...

 
 
 
Regeneron Touts Success in Big Asthma Drug Study, Plans FDA Filing

REGENERON TOUTS SUCCESS IN BIG ASTHMA DRUG STUDY, PLANS FDA FILING

A new drug for patients who have a hard time controlling their asthma could be nearing an FDA review. Tarrytown, NY-based Regeneron...